History
-
2022 Q4
- ㆍPublished SCI-journal review paper about spinal cord injury therapy based on Direct Lineage Reprogramming Technology
- ㆍResearch contract with Molim INC for immunogenicity test
- ㆍResearch contract with H-Bio INC
- ㆍResearch contract with Yonsei University
Industry-Academic Cooperation Foundation
- ㆍSelected for National Advanced Regenerative Medicine Project
- ㆍCompleted GLP-compliant non-clinical toxicity evaluation
(Non-Toxicity Determined)
-
2022 Q3
- ㆍGMP-grade AAV production with VectorBuilder
- ㆍPaper in world renowned journal Acta Biomaterialia (IF : 10.66)
- ㆍSelected for National New Drug Development Project
- ㆍVenture Certification
-
2022 Q2
- ㆍFamily sales funding contract
- ㆍResearch contract with KIST
(Korea Institute of Science and Technology)
- ㆍResearch contract with Kyungki University
(Biodistribution for toxicity evaluation)
- ㆍResearch contract with Chemon INC
(Non-clinical toxicity evaluation)
-
2022 Q1
- ㆍEstablishment of Research Institute
- ㆍCertification of ISO 9001/14001
- ㆍRegistration of BSL-2 (Central laboratory facility)
- ㆍRegistration of ABSL-2 (Animal laboratory)
- ㆍPatent advisory contract with Patent Law-Firm IPLAY
-
2021
- ㆍStand Up Therapeutics INC Established
- ㆍResearch Laboratory Open
2013
- A Study on the Direct Lineage Reprogramming(DLR)
of induced neurons(iNs) for the neurodegenerative disease gene therapy
